PMID- 31251441
OWN - NLM
STAT- MEDLINE
DCOM- 20200305
LR  - 20200305
IS  - 1476-5829 (Electronic)
IS  - 1476-5810 (Linking)
VI  - 17
IP  - 4
DP  - 2019 Dec
TI  - Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment 
      for dogs with metastatic splenic hemangiosarcoma: A multi-institutional 
      retrospective study of the Italian Society of Veterinary Oncology.
PG  - 537-544
LID - 10.1111/vco.12519 [doi]
AB  - Treatment options for dogs with metastatic (stage III) splenic hemangiosarcoma 
      are limited. A doxorubicin-based chemotherapy regimen is commonly administered; 
      however, there are no published data to support this practice. The aim of this 
      study was to investigate the impact of maximum-tolerated-dose chemotherapy (MTD), 
      metronomic chemotherapy (MC) and no adjuvant treatment on outcome in dogs with 
      stage III splenic hemangiosarcoma undergoing splenectomy. Medical records of dogs 
      with stage III splenic hemangiosarcoma that underwent splenectomy followed by MTD 
      chemotherapy, MC or no adjuvant treatment were retrieved. Time to progression 
      (TTP), survival time (ST) and toxicity were evaluated. One hundred three dogs 
      were identified: 23 received adjuvant MTD, 38 MC and 42 were not medically 
      treated. Overall median TTP and ST were 50 (95% confidence interval [CI], 39-61) 
      and 55 days (95% CI, 43-66), respectively. Dogs treated with adjuvant MTD had a 
      significantly longer TTP and ST compared with dogs receiving MC (median TTP, 134 
      vs 52 days, P = .025; median ST, 140 vs 58 days, P = .023, respectively). Dogs 
      treated by splenectomy only had the shortest median TTP (28 days) and ST (40 
      days). However, treatment-related adverse events (AEs) were significantly more 
      frequent in the MTD group (P = .017). The outcome for dogs with metastatic 
      splenic hemangiosarcoma is poor. While MTD showed greater efficacy compared to 
      MC, toxicity was higher in this group. Treatment-related AEs need to be carefully 
      balanced against this modest survival prolongation when offering adjuvant MTD to 
      dogs with advanced stage hemangiosarcoma.
CI  - (c) 2019 John Wiley & Sons Ltd.
FAU - Marconato, Laura
AU  - Marconato L
AUID- ORCID: 0000-0002-7843-615X
AD  - Centro Oncologico Veterinario, Bologna, Italy.
FAU - Chalfon, Carmit
AU  - Chalfon C
AD  - Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
FAU - Finotello, Riccardo
AU  - Finotello R
AD  - Department of Small Animal Clinical Science, Institute of Veterinary Science, 
      University of Liverpool, Neston, UK.
FAU - Polton, Gerry
AU  - Polton G
AD  - North Downs Specialist Referrals, Bletchingley, UK.
FAU - Vasconi, Maria E
AU  - Vasconi ME
AD  - Centro Veterinario Torinese, Turin, Italy.
FAU - Annoni, Maurizio
AU  - Annoni M
AD  - Clinica Veterinaria Tibaldi, Milan, Italy.
FAU - Stefanello, Damiano
AU  - Stefanello D
AUID- ORCID: 0000-0003-2726-0366
AD  - Department of Veterinary Medicine, University of Milan, Milan, Italy.
FAU - Mesto, Paola
AU  - Mesto P
AD  - Centro Medico Veterinario BMVet, Bari, Italy.
FAU - Capitani, Ombretta
AU  - Capitani O
AD  - Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
FAU - Agnoli, Chiara
AU  - Agnoli C
AD  - Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
FAU - Amati, Maria
AU  - Amati M
AD  - Ospedale Veterinario Citta di Pavia, Pavia, Italy.
FAU - Sabattini, Silvia
AU  - Sabattini S
AUID- ORCID: 0000-0001-7005-2736
AD  - Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20190709
PL  - England
TA  - Vet Comp Oncol
JT  - Veterinary and comparative oncology
JID - 101185242
RN  - 0 (Antineoplastic Agents)
RN  - 5J49Q6B70F (Vincristine)
RN  - 7GR28W0FJI (Dacarbazine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
SB  - IM
MH  - Administration, Metronomic/veterinary
MH  - Animals
MH  - Antineoplastic Agents/administration & dosage/classification/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & 
      dosage/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Cyclophosphamide/administration & dosage/therapeutic use
MH  - Dacarbazine/administration & dosage/therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Doxorubicin/administration & dosage/therapeutic use
MH  - Female
MH  - Hemangiosarcoma/therapy/*veterinary
MH  - Male
MH  - Retrospective Studies
MH  - Splenic Neoplasms/therapy/*veterinary
MH  - Treatment Outcome
MH  - Vincristine/administration & dosage/therapeutic use
OTO - NOTNLM
OT  - dog
OT  - hemangiosarcoma
OT  - maximum tolerated chemotherapy
OT  - metastasis
OT  - metronomic chemotherapy
OT  - prognosis
EDAT- 2019/06/30 06:00
MHDA- 2020/03/07 06:00
CRDT- 2019/06/29 06:00
PHST- 2019/02/11 00:00 [received]
PHST- 2019/06/23 00:00 [revised]
PHST- 2019/06/24 00:00 [accepted]
PHST- 2019/06/30 06:00 [pubmed]
PHST- 2020/03/07 06:00 [medline]
PHST- 2019/06/29 06:00 [entrez]
AID - 10.1111/vco.12519 [doi]
PST - ppublish
SO  - Vet Comp Oncol. 2019 Dec;17(4):537-544. doi: 10.1111/vco.12519. Epub 2019 Jul 9.